
1. malar j. 2019 aug 28;18(1):293. doi: 10.1186/s12936-019-2919-3.

low polymorphisms pfact, pfugt pfcarl genes african plasmodium
falciparum isolates absence association susceptibility common
anti-malarial drugs.

foguim ft(1)(2)(3), robert mg(1)(2)(3), gueye mw(4), gendrot m(1)(2)(3), diawara 
s(4), mosnier j(1)(2)(3)(5), amalvict r(1)(2)(3)(5), benoit n(1)(2)(3)(5),
bercion r(6), fall b(4), madamet m(1)(2)(3)(5), pradines b(7)(8)(9)(10)(11);
french national reference centre imported malaria study group.

collaborators: augis v, basset d, bastien p, benoit-vical f, berry a, brouqui p, 
cividin m, delaunay p, delhaes l, drancourt m, gaillard t, genin a, garnotel e,
javelle e, l'ollivier c, leveque m, malvy d, marty p, mechain m, ménard g, millet
p, minodier p, mottard a, parola p, piarroux r, pomares-estran c, receveur mc,
robin a, sappa e, savini h, simon f, sterkers y, surcouf c, varlet e, wolff a.

author information: 
(1)unité parasitologie et entomologie, département de microbiologie et de
maladies infectieuses, institut de recherche biomédicale des armées, ihu
méditerranée infection, 19-21 boulevard jean moulin, 13005, marseille, france.
(2)ird, ssa, ap-hm, vitrome, aix marseille université, marseille, france.
(3)ihu méditerranée infection, marseille, france.
(4)fédération des laboratoires, hôpital principal de dakar, dakar, senegal.
(5)centre national de référence du paludisme, marseille, france.
(6)laboratoire d'analyses médicales, institut pasteur de dakar, dakar, senegal.
(7)unité parasitologie et entomologie, département de microbiologie et de
maladies infectieuses, institut de recherche biomédicale des armées, ihu
méditerranée infection, 19-21 boulevard jean moulin, 13005, marseille, france.
bruno.pradines@gmail.com.
(8)ird, ssa, ap-hm, vitrome, aix marseille université, marseille, france.
bruno.pradines@gmail.com.
(9)ihu méditerranée infection, marseille, france. bruno.pradines@gmail.com.
(10)fédération des laboratoires, hôpital principal de dakar, dakar, senegal.
bruno.pradines@gmail.com.
(11)centre national de référence du paludisme, marseille, france.
bruno.pradines@gmail.com.

background: resistance available anti-malarial drugs emerged and
spread including artemisinin derivatives partner drugs. several genes
involved artemisinin partner drugs resistance, pfcrt, pfmdr1,
pfk13 pfpm2, identified. however, genes properly
explain anti-malarial drug resistance, particularly clinical failures
observed africa. mutations genes encoding plasmodium falciparum
proteins, p. falciparum acetyl-coa transporter (pfact), p. falciparum
udp-galactose transporter (pfugt) p. falciparum cyclic amine resistance locus
(pfcarl) recently associated resistance imidazolopiperazines 
other unrelated drugs.
methods: mutations pfugt, pfact pfcarl characterized 86 isolates
collected dakar, senegal 173 samples collected patients hospitalized 
in france travel african countries 2015 2016 assess 
potential association ex vivo susceptibility chloroquine, quinine,
lumefantrine, monodesethylamodiaquine, mefloquine, dihydroartemisinin,
artesunate, doxycycline, pyronaridine piperaquine.
results: mutations found genes pfugt pfact. none pfcarl
described mutations identified samples africa. k784n
mutation found one sample k734m mutation identified 7.9% of
all samples pfcarl. significant differences ex vivo
susceptibility according k734m mutation observed pyronaridine for
african isolates imported malaria doxycycline senegalese
parasites.
conclusion: evidence found involvement genes reduced
susceptibility standard anti-malarial drugs african p. falciparum isolates.

doi: 10.1186/s12936-019-2919-3 
pmcid: pmc6712813
pmid: 31455301  [indexed medline]

